Log in

Relevant bibliographies by topics / Grazoprevir / Journal articles

To see the other types of publications on this topic, follow the link: Grazoprevir.

Journal articles on the topic 'Grazoprevir'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Grazoprevir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Seetharamaiah, P., Nagaraju Pappula, G. Poornima, and G. Chandanashree. "Development and Validation of new RP-HPLC Method for the Simultaneous Estimation of Elbasvir and Grazoprevir in Combined Pharmaceutical Dosage Form." Journal of Pharmaceutical Research 22, no. 3 (2023): 172–77. http://dx.doi.org/10.18579/jopcr/v22.3.22.6.

Full text

Abstract:

A reliable and exact technique was formulated for concurrently determining Elbasvir and Grazoprevir in tablet dosage forms. Chromatogram was developed by running a sample through Zodiac C18 column (4.6 x 150 mm, 5 µm) with the mobile phase containing Orthophosphoric acid (0.1%) and Acetonitrile in the ratio 50:50 v/v. The solution was pumped through the column at a flow rate of 1 ml/min, while maintaining the column temperature at 30°C. The optimized wavelength selected was 260 nm. The retention times for Elbasvir and Grazoprevir were determined to be 2.32 min and 3.30 min, respectively. The p

APA, Harvard, Vancouver, ISO, and other styles

2

Lahser, Frederick C., Karin Bystol, Stephanie Curry, et al. "The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons." Antimicrobial Agents and Chemotherapy 60, no. 5 (2016): 2954–64. http://dx.doi.org/10.1128/aac.00051-16.

Full text

Abstract:

ABSTRACTThe selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence of resistance. The combination of grazoprevir (formerly MK-5172), an NS3/4A protease inhibitor, and elbasvir (formerly MK-8742), an NS5A inhibitor, was therefore studied in genotype 1a (GT1a) replicon cells. Both compounds were independently highly potent in GT1a wild-type replicon cells, wi

APA, Harvard, Vancouver, ISO, and other styles

3

Pijnenburg, Daniëlle W. M., Minou van Seyen, Evertine J. Abbink, Angela Colbers, Joost P. H. Drenth, and David M. Burger. "Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection." Journal of Antimicrobial Chemotherapy 75, no. 9 (2020): 2661–65. http://dx.doi.org/10.1093/jac/dkaa230.

Full text

Abstract:

Abstract Background Finding a suitable treatment for HCV patients with swallowing disorders is still a major challenge. In practice, direct-acting antivirals are crushed without knowledge of adequate absorption. Crushing can alter drug exposure, possibly leading to treatment failure, development of resistance or toxicity. Currently, there is no information about crushing of the fixed-dose combination tablet of elbasvir/grazoprevir; therefore, crushing of this tablet is not recommended. Objectives To investigate the influence of crushing on the pharmacokinetics of the elbasvir/grazoprevir fixed

APA, Harvard, Vancouver, ISO, and other styles

4

Cada, Dennis J., Anne P. Kim, and Danial E. Baker. "Elbasvir/Grazoprevir." Hospital Pharmacy 51, no. 8 (2016): 665–86. http://dx.doi.org/10.1310/hpj5108-665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pallapati, Suman1 2* Tirukkovalluri Siva Rao1 Kallam Venkata Siva Rama Krishna Reddy2. "HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF ANTIVIRAL DRUGS, GRAZOPREVIR AND ELBASVIR, SIMULTANEOUSLY IN BULK AND IN TABLETS." INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH 07, no. 09 (2017): 464–70. https://doi.org/10.5281/zenodo.1036470.

Full text

Abstract:

The current investigation described a sensitive, selective, precise and accurate RP-HPLC method with photodiode array detector for the simultaneous estimation of antiviral drugs, grazoprevir and elbasvir. The separation and analysis were done on Sunsil C18 analytical column (250 mm x 4.6 mm, 5 μ particle size). 0.1M NaH2PO4: methanol [60:40 v/v] in isocratic elution mode was used as mobile phase. The pH of the mobile was adjusted to 4.0 with orthophosphoric acid. The elution of grazoprevir and elbasvir was accomplished with a flow rate of 1.2 ml/min. Detection was performed with photodiode arr

APA, Harvard, Vancouver, ISO, and other styles

6

Kumar, V. Pavan, A. Vijaya Kumar, B. Sivagami, R. Charan Kumar, and M. Niranjan Babu. "Stability indicating RP-HPLC method development and validation for the simultaneous estimation of Grazoprevir and Elbasvir in bulk and pharmaceutical dosage form." International Journal of Research In Pharmaceutical Chemistry and Analysis 1, no. 1 (2018): 1–7. http://dx.doi.org/10.33974/ijrpca.v1i1.4.

Full text

Abstract:

A simple, Accurate and precise method was developed for the simultaneous estimation of the Grazoprevir and Elbasvir in Tablet dosage form. Chromatogram was run through Kromosil C18 (250 x 4.6 mm), 5m. Mobile phase containing Buffer: Acetonitrile taken in the ratio 45:55 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was Di Potassium Hydrogen ortho Phosphate. Temperature was maintained at 30°C. Optimized wavelength selected was 215 nm. Retention time of Elbasvir and Grazoprevir and were found to be 2.503 min and 3.004. %RSD of the Elbasvir and Grazoprevir were

APA, Harvard, Vancouver, ISO, and other styles

7

Guo, Zifang, Luzelena Caro, Michael N. Robertson, et al. "The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir." Pharmacogenomics 20, no. 9 (2019): 631–41. http://dx.doi.org/10.2217/pgs-2019-0022.

Full text

Abstract:

Aim: To evaluate the effect of SLCO1B1 genetic variants on grazoprevir pharmacokinetics and efficacy. Methods: A retrospective analysis of 1578 hepatitis C virus-infected participants from ten Phase II/III clinical trials. Results: Relative to noncarriers of the risk allele, geometric mean ratios (95% CI) of grazoprevir area under curve (AUC)0–24 were: rs4149056 (risk allele C), one copy, 1.13 (1.06–1.21), two copies, 1.43 (1.16–1.77); and rs11045819 (risk allele A), one copy, 0.93 (0.87–1.00); two copies, 0.78 (0.61–1.00). The rs2306283 variant was not associated with grazoprevir exposure. No

APA, Harvard, Vancouver, ISO, and other styles

8

Swapna.Goday*, S.K.Abdul Rahaman A.Prameelarani. "FORCED DEGRADATION STUDIES DEVELOPMENT AND VALIDATION BY RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF COMBINATION DRUGS ELBASVIR AND GRAZOPREVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS." Indo American Journal of Pharmaceutical Sciences 04, no. 08 (2017): 2526–33. https://doi.org/10.5281/zenodo.848507.

Full text

Abstract:

A Stability-indicating reverse phase – high performance liquid chromatography(RP-HPLC) method was developed and validated for the determination of Elbasvir and Grazoprevir in tablet dosage forms using C18 column Discovery( 250x4.6 mm, 5 µ) with a mobile phase consisting of orthophosphoric acid and methanol (45:55% v/v). The pH was adjusted to 3.8 with dil. NaoH.The mobile phase was sonicated for 10min and filtered through a 0.45µm membrane filter at a flow rate of 1.0 ml/min.The Detection was carried out at 220nm and retention time of Grazoprevir was found to be 2.3min ,and retention time of E

APA, Harvard, Vancouver, ISO, and other styles

9

Yao, Yinan, Ming Yue, Jie Wang, et al. "Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis." Canadian Journal of Gastroenterology and Hepatology 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/8186275.

Full text

Abstract:

Background. It is urgent for patients with hepatitis C virus (HCV) infection to find a safe, effective, and interferon-free regimen to optimize therapy. A comprehensive analysis was performed to evaluate the efficacy and safety of the grazoprevir combined with elbasvir, with or without ribavirin (RBV), in 777 treatment-naive and treatment-experienced patients with HCV genotype 1 infection from 3 randomized controlled trials (RCTs). Method. We collected data from the following trials: C-WORTHY (NCT01717326), C-SALVAGE (NCT02105454), and C-EDGE (NCT02105467). All patients received grazoprevir pl

APA, Harvard, Vancouver, ISO, and other styles

10

Srisailam, Nakka, Narmada Vallakeerthi, Revathy Sundara Moorthy, and Kavitha Marapakala. "Simultaneous RP-HPLC Estimation, Validation and Stability Indicating Assay of Two-Component Tablet Formulation Containing Grazoprevir and Pibrentasvir." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 02 (2024): 895–900. http://dx.doi.org/10.25258/ijpqa.15.2.55.

Full text

Abstract:

The determination of a two-component tablet formulation containing grazoprevir and pibrentasvir for method development and validation has been done using the reverse-phase high-performance liquid chromatography (RP-HPLC) method as per International Council of Harmonization (ICH) guidelines. Analytical grade acetonitrile and 0.01 N of potassium dihydrogen phosphate buffer were used as mobile phase while Kromasil C18 column was opted for separation. In order to elute the analyte a flow rate of 1-mL/min having 260 nm λ has been maintained. An RT of 2.909 and 2.358 minutes while linearity concentr

APA, Harvard, Vancouver, ISO, and other styles

11

B., Manoja *. V. Abhishiktha B. Madhavi Latha Dr. D. Satyavati T. Lalitha. "DEVELOPMENT AND VALIDATION OF A RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF ELBASVIR AND GRAZOPREVIR IN PURE AND PHARMACEUTICAL DOSAGE FORM." Journal of Scientific Research in Pharmacy 7, no. 8 (2018): 92–95. https://doi.org/10.5281/zenodo.1326526.

Full text

Abstract:

<strong><em>ABSTRACT</em></strong> <strong><em>A</em></strong><em> rapid and precise reverse phase high performance liquid chromatographic method has been developed for the validated of Elbasvir and Grazoprevir, in its pure form as well as in tablet dosage form. Chromatography was carried out on a Zorbax C18 (4.6 x 150mm, 5µm) column using a mixture of Methanol: Phosphate Buffer pH 3.9 (55:45v/v) as the mobile phase at a flow rate of 1.0ml/min, the detection was carried out at 255nm. The retention time of the Elbasvir and Grazoprevir was </em><em>2.061, 2.462 </em><em>±0.02min res

APA, Harvard, Vancouver, ISO, and other styles

12

Dandu, Girija, and Basu Venkateswara Reddy. "DEVELOPMENT AND VALIDATION OF NEW STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM." INDIAN DRUGS 57, no. 09 (2020): 53–59. http://dx.doi.org/10.53879/id.57.09.11644.

Full text

Abstract:

The present study describes the development and validation of a new stability indicating RP-HPLC method for simultaneous estimation of elbasvir and grazoprevir in bulk and pharmaceutical dosage form. The chromatographic separation was done by using reverse phase YMC column (4.6 x 250mm, 5μm).The mobile phase used was mixture of HPLC grade water acetonitrile (70:30V/V) at flow rate of 1ml/ min in isocratic mode and detection was carried out using PDA detector at 244nm.The developed method showed a good linearity in the range of 100-500μg/mL for elbasvir and 200-1000 μg/mL for grazoprevir with r

APA, Harvard, Vancouver, ISO, and other styles

13

Laksono, Bayu, Nenny Agustanti, Rudi Supriyadi, Muhammad Begawan Bestari, and Siti Aminah Abdurachman. "Reduction of Liver Fibrosis After Treatment with Elbasvir/Grazoprevir in Patients with Hepatitis C Infection in Chronic Kidney Disease on Hemodialysis, a Quasi-Experimental Study." Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 22, no. 1 (2021): 21–28. http://dx.doi.org/10.24871/221202121-28.

Full text

Abstract:

Background: Approximately 5-60% of hemodialysis patients have comorbid of hepatitis C virus (HCV) infection. The survival rate of hemodialysis patients HCV is lower than those without HCV due to the risk of liver fibrosis and cardiovascular disease. The combination of Elbasvir and Grazoprevir is the drug of choice for these patients with HCV genotype 1 and 4 which mainly inherited in populations in Indonesia. However, a high cost is required for this genome testing. Eradication of HCV might reduce liver fibrosis. One of the methods to evaluate liver fibrosis is by using APRI score. The aim of

APA, Harvard, Vancouver, ISO, and other styles

14

Attia, Khalid A. M., Ahmed El-Olemy, Sherif Ramzy, et al. "Development and validation of a highly sensitive second derivative synchronous fluorescence spectroscopic method for the simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation and human plasma." New Journal of Chemistry 44, no. 43 (2020): 18679–85. http://dx.doi.org/10.1039/d0nj03636f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Keating, Gillian M. "Elbasvir/Grazoprevir: First Global Approval." Drugs 76, no. 5 (2016): 617–24. http://dx.doi.org/10.1007/s40265-016-0558-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

DeCarolis, Douglas D., Yi-Chieh Chen, Anders D. Westanmo, Christopher Conley, Amy A. Gravely, and Fatima B. Khan. "Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection." American Journal of Health-System Pharmacy 76, no. 17 (2019): 1273–80. http://dx.doi.org/10.1093/ajhp/zxz127.

Full text

Abstract:

Abstract Purpose We previously reported an interaction with warfarin anticoagulation when initiating treatment with direct-acting antiviral agents for hepatitis C infection. A decreased warfarin sensitivity led to subtherapeutic anticoagulation. To study this interaction further, we expanded our research to include patients treated with the combination of elbasvir and grazoprevir concurrent with warfarin anticoagulation and investigated changes in warfarin sensitivity during and after treatment. Methods Using electronic health records of the Veterans Health Administration, patients starting tr

APA, Harvard, Vancouver, ISO, and other styles

17

Huang, Chung-Feng, Chao-Hung Hung, Pin-Nan Cheng, et al. "An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions." Journal of Infectious Diseases 220, no. 4 (2019): 557–66. http://dx.doi.org/10.1093/infdis/jiz154.

Full text

Abstract:

AbstractBackgroundA 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive HCV-1–infected patients with mild fibrosis has not been determined.MethodsTreatment-naive HCV-1b–infected patients with mild fibrosis were randomly assigned to receive 8 (n = 41) or 12 (n = 41) weeks of grazoprevir/elbasvir therapy. The primary end point was a sustained virologic response, defined as an HCV RNA level of < 12 IU/mL, at posttreatment week 12 (SVR12).ResultsSVR12 was achieved by 87.8% of patie

APA, Harvard, Vancouver, ISO, and other styles

18

Bell, Allison M., Jamie L. Wagner, Katie E. Barber, and Kayla R. Stover. "Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C." International Journal of Hepatology 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/3852126.

Full text

Abstract:

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosi

APA, Harvard, Vancouver, ISO, and other styles

19

Hussar, Daniel A., and William P. Tidwell. "Elbasvir/grazoprevir, Velpatasvir/sofosbuvir, and Eteplirsen." Journal of the American Pharmacists Association 57, no. 1 (2017): 129–32. http://dx.doi.org/10.1016/j.japh.2016.11.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Khalil, Roaa, Kholoud Al-Mahzoum, Muna Barakat, and Malik Sallam. "An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences." Pathogens 13, no. 8 (2024): 674. http://dx.doi.org/10.3390/pathogens13080674.

Full text

Abstract:

Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment. This study aimed to assess the prevalence and temporal trends of RASs in HCV, with a particular focus on clinically relevant RASs (cr-RASs). Near-complete HCV GenBank sequences archived in the Los Alamos HCV Database were analyzed. The study period was divided into two phases: before 2011 and from 2011 onward. Identification of RASs across three DAA classes (NS3, NS5A, and NS5B inhibit

APA, Harvard, Vancouver, ISO, and other styles

21

S, Madhavi, and Prameela Rani A. "SIMULTANEOUS REVERSE-PHASE ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF GRAZOPREVIR AND ELBASVIR." Asian Journal of Pharmaceutical and Clinical Research 11, no. 4 (2018): 100. http://dx.doi.org/10.22159/ajpcr.2018.v11i4.21721.

Full text

Abstract:

Objective: The objective of this study was to develop and validate rapid, specific, sensitive, and precise reverse-phase ultra performance liquid chromatography (RP-UPLC) method for the quantitative determination of grazoprevir and elbasvir, as there are no official monograph and no analytical method by UPLC.Methods: Chromatographic separation was achieved on a Waters Acquity UPLC HSS C18 (2.1 mm × 100 mm, 1.8 micron) column with a 45:55 (v/v) mixture of 0.1% orthophosphoric acid (pH 2.8) and acetonitrile as a mobile phase, thermostated at 30°C with a short run time of 3.0 min.Results: The ret

APA, Harvard, Vancouver, ISO, and other styles

22

Mattingly, T. Joseph, Julia F. Slejko, and C. Daniel Mullins. "Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?" Annals of Pharmacotherapy 51, no. 11 (2017): 961–69. http://dx.doi.org/10.1177/1060028017722007.

Full text

Abstract:

Background: Numerous economic models have been published evaluating treatment of chronic hepatitis C virus (HCV) infection, but none provide a comprehensive comparison among new antiviral agents. Objective: Evaluate the cost-effectiveness of all recommended therapies for treatment of genotypes 1 and 4 chronic HCV. Methods: Using data from clinical trials, observational analyses, and drug pricing databases, Markov decision models were developed for HCV genotypes 1 and 4 to compare all recommended drugs from the perspective of the third-party payer over a 5-, 10-, and 50-year time horizon. A pro

APA, Harvard, Vancouver, ISO, and other styles

23

Mustika, Syifa, Yhang Lidi Tama, and Zuhrotus Sholichah. "The efficacy of administering elbasvir/grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid of hypertension and diabetes mellitus." Jurnal Penyakit Dalam Udayana 7, no. 2 (2023): 35–38. http://dx.doi.org/10.36216/jpd.v7i2.228.

Full text

Abstract:

Background: Hepatitis C and chronic kidney disease (CKD) are significant global health burdens. Hemodialysis therapy can pose a risk of hepatitis C infection. Conditions related to Hepatitis C, such as hypertension and diabetes, have morbidity and mortality rates and can impact the outcomes of hepatitis C treatment. Objective: This study aimed to assess the efficacy of Elbasvir/Grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid hypertension and diabetes mellitus. Methods: The target population for this study consists of hepatitis C-infected patients undergoing routine he

APA, Harvard, Vancouver, ISO, and other styles

24

Vallet-Pichard, Anaïs, and Stanislas Pol. "Grazoprevir/elbasvir combination therapy for HCV infection." Therapeutic Advances in Gastroenterology 10, no. 1 (2016): 155–67. http://dx.doi.org/10.1177/1756283x16671293.

Full text

Abstract:

Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or paritaprevir boosted by ritonavir), NS5B nucleos(t)idic (sofosbuvir) and nonnucleos(t)idic (dasabuvir) polymerase inhibitors, NS5A replication complex inhibitors (daclatasvir, ledipasvir, elbasvir, velpatasvir). Combinations of two or three DAAs, given for 8–24 weeks reach sustained virology response (SVR) rates greater than 90% with good tolerance. SVR rates and

APA, Harvard, Vancouver, ISO, and other styles

25

Sheikh, Sabahat Yasmeen, Waseem Ahmad Ansari, Firoj Hassan, et al. "Drug Repurposing against Phosphomannomutase for the Treatment of Cutaneous Leishmaniasis." Oriental Journal Of Chemistry 39, no. 1 (2023): 01–10. http://dx.doi.org/10.13005/ojc/390101.

Full text

Abstract:

Due to the lack of approved vaccines against Cutaneous leishmaniasis (CL), chemotherapy is the only treatment option. Presently, none of the current CL drugs have high levels of efficacy and safety profiles. Thus, the development of new and safer drugs is urgently needed. Drug repurposing can be used for the development of new therapeutic activities. Phosphomannomutase (PMM) has become highlighted as a potential drug target due to its important role in the biosynthesis of glycoconjugates which is essential for parasite virulence. To identify new promising lead molecules, we have performed virt

APA, Harvard, Vancouver, ISO, and other styles

26

Hsu, Po-Yao, Yu-Ju Wei, Jia-Jung Lee, et al. "Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis." Clinical and Molecular Hepatology 27, no. 1 (2021): 186–96. http://dx.doi.org/10.3350/cmh.2020.0180.

Full text

Abstract:

Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.Methods: The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.Results: Of 2,015 hemodialysis patients screened in 2019, 169 patients sero

APA, Harvard, Vancouver, ISO, and other styles

27

Jensen, Sanne B., Stéphanie B. N. Serre, Daryl G. Humes, et al. "Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance." Antimicrobial Agents and Chemotherapy 59, no. 12 (2015): 7426–36. http://dx.doi.org/10.1128/aac.01953-15.

Full text

Abstract:

ABSTRACTVarious protease inhibitors (PIs) currently are becoming available for treatment of hepatitis C virus (HCV). For genotype 1, substitutions at NS3 protease positions 155, 156, and 168 are the main determinants of PI resistance. For other genotypes, similar substitutions were selected during PI treatment but were not characterized systematically. To elucidate the impact of key PI resistance substitutions on genotypes 2 to 6, we engineered the substitutions R155A/E/G/H/K/Q/T, A156G/S/T/V, and D/Q168A/E/G/H/N/V into HCV recombinants expressing genotype 2 to 6 proteases. We evaluated viral

APA, Harvard, Vancouver, ISO, and other styles

28

Bhangale, Charushila, Sachin Somwanshi, Kiran Kotade, and Mayur Gaikar. "Eco-Friendly Stability Indicating HPLC Method for Estimation of Elbasvir and Grazoprevir by Quality by Design Approach." Journal of Advanced Zoology 44, S-5 (2023): 1330–46. http://dx.doi.org/10.17762/jaz.v44is-5.1261.

Full text

Abstract:

Introduction: The pharmaceutical industry faces a significant problem as a result of the worldwide requirement to modify processes in order to comply with the green analytical chemistry (GAC) requirements. An enormous amount of organic hazardous waste is produced by high-performance liquid chromatography (HPLC), one of the methods employed the most frequently at different stages in the pharmaceutical sector. Aim: To develop analytical quality by design-aided stability indicating green high-performance liquid chromatography (HPLC) method for estimation of Elbasvir and Grazoprevir in a dosage fo

APA, Harvard, Vancouver, ISO, and other styles

29

Gamal, N., and P. Andreone. "Grazoprevir/elbasvir fixed-dose combination for hepatitis C." Drugs of Today 52, no. 7 (2016): 377. http://dx.doi.org/10.1358/dot.2016.52.7.2510258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Hofmann-Aßmus, Marion. "Hepatitis C: Kurztherapie mit Fixkombination Elbasvir/Grazoprevir ausreichend?" Zeitschrift für Gastroenterologie 55, no. 03 (2017): 236. http://dx.doi.org/10.1055/s-0043-100920.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Chotiyaputta, Watcharasak. "Hepatitis debrief from AASLD 2017." Thai Journal of Hepatology 1, no. 1 (2018): 39–41. http://dx.doi.org/10.30856/th.jhep2018vol1iss1_10.

Full text

Abstract:

งานประชุมโรคตับ American Association for the Study of Liver Diseases (AASLD) เมื่อปี 2017 มีงานวิจัยที่เกี่ยวข้องกับโรคไวรัสตับอักเสบต่างๆ โดยการศึกษาที่เกี่ยวข้องกับโรคไวรัสตับอักเสบ ซี มีมากสุด เป็นงานที่เกี่ยวกับการให้ยา Direct acting antivirals (DAA) ชนิดต่างๆ ได้แก่ ยา Sofosbuvir/Velpatasvir/Volxilaprevir, Glecaprevir/Pibrentasvir, Sofosbuvir/Ledipasvir และ Elbasvir/Grazoprevir ใช้ในการรักษาไวรัสตับอักเสบ ซี สายพันธุ์ต่างๆ ได้ผลการรักษาดี ส่วนการศึกษาอื่นๆ ได้แก่ความสัมพันธ์ของผู้ป่วยโรคไวรัสตับอักเสบ ซี หลังได้ยา DAA ต่อการติดเชื้อซ้ำและการเกิดโรคมะเร็งตับ สำหรับการติดเชื้อไวรัสตับอักเสบ

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Szu-Jen, Chung-Feng Huang, and Ming-Lung Yu. "Elbasvir and grazoprevir for the treatment of hepatitis C." Expert Review of Anti-infective Therapy 19, no. 9 (2021): 1071–81. http://dx.doi.org/10.1080/14787210.2021.1874351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Martin, Michelle T., and Sean Koppe. "Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis." Transplantation 101, no. 9 (2017): 2088–91. http://dx.doi.org/10.1097/tp.0000000000001758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sanaka, Sirish, Charles Rives, Hossein Movahed, Glenn Harvin, and Sabeen Abid. "Fatal Drug-Induced Pneumonitis With Use of Elbasvir-Grazoprevir." American Journal of Gastroenterology 112 (October 2017): S1265. http://dx.doi.org/10.14309/00000434-201710001-02315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kiang, Tony K. L. "Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir." European Journal of Drug Metabolism and Pharmacokinetics 43, no. 5 (2018): 509–31. http://dx.doi.org/10.1007/s13318-018-0471-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Zhdanov, Konstantin, Vasily Isakov, Eduard Burnevich, et al. "Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial." Hepatic Medicine: Evidence and Research Volume 12 (April 2020): 61–68. http://dx.doi.org/10.2147/hmer.s241418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Chen, Jin, Yi Li, Guisen Li, and Pu Lei. "Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient." Renal Failure 42, no. 1 (2020): 377–80. http://dx.doi.org/10.1080/0886022x.2020.1753073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Alric, Laurent, and Delphine Bonnet. "Grazoprevir + elbasvir for the treatment of hepatitis C virus infection." Expert Opinion on Pharmacotherapy 17, no. 5 (2016): 735–42. http://dx.doi.org/10.1517/14656566.2016.1161028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Belhassen, M., A. Clement, E. Guidoum, J. Dallongeville, M. Bérard, and L. Serfaty. "PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE." Value in Health 21 (October 2018): S311. http://dx.doi.org/10.1016/j.jval.2018.09.1853.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Xu, Feng, Yong-Li Zhong, Hongming Li, et al. "Asymmetric Synthesis of Functionalized trans-Cyclopropoxy Building Block for Grazoprevir." Organic Letters 19, no. 21 (2017): 5880–83. http://dx.doi.org/10.1021/acs.orglett.7b02867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Mc Combs, J. S., J. McGinnis, S. Fox, and I. Tonnu-Mihara. "Analysis of the real-world treatment effectiveness of elbasvir/grazoprevir." Journal of Hepatology 66, no. 1 (2017): S515—S516. http://dx.doi.org/10.1016/s0168-8278(17)31433-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Papudesu, Chandana, Shyamasundaran Kottilil, and Shashwatee Bagchi. "Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection." Hepatology International 11, no. 2 (2016): 152–60. http://dx.doi.org/10.1007/s12072-016-9761-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Dunaeva, N. V., M. A. Chirskaya, E. Yu Kolpashchikova, et al. "Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V." Journal Infectology 12, no. 1 (2020): 104–10. http://dx.doi.org/10.22625/2072-6732-2020-12-1-104-110.

Full text

Abstract:

The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development of mixed type III cryoglobulinemia, cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic vasculitis), and the liver (alternatively proliferative vasculitis) is demonstrated. The introduction of daclatasvir + asunaprevir was virologically unsuccessful: mutations D168E and L31V were detected against the background of a virological breakthrough. A repeated course of antiviral therapy with the combination of Grazoprevir + Elbasvir in combination wit

APA, Harvard, Vancouver, ISO, and other styles

44

Boyd, Anders, Patrick Miailhes, Julie Chas, et al. "Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM." Journal of Antimicrobial Chemotherapy 75, no. 7 (2020): 1961–68. http://dx.doi.org/10.1093/jac/dkaa091.

Full text

Abstract:

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks aft

APA, Harvard, Vancouver, ISO, and other styles

45

Attia, Khalid A. M., Nasr M. El-Abasawi, Ahmed El-Olemy, and Ahmed H. Abdelazim. "Simultaneous Spectrophotometric Determination of Elbasvir and Grazoprevir in a Pharmaceutical Preparation." Journal of AOAC INTERNATIONAL 101, no. 2 (2018): 394–400. http://dx.doi.org/10.5740/jaoacint.17-0037.

Full text

Abstract:

Abstract Three UV spectrophotometric methods have been developed for the simultaneous determination of two new Food and Drug Administration-approved drugs, elbasvir (EBV) and grazoprevir (GRV), in their combined pharmaceutical dosage form. These methods include dual wavelength (DW), classic least-squares (CLS), and principal component regression (PCR). To achieve the DW method, two wavelengths were chosen for each drug in a way to ensure the difference in absorbance was zero from one drug to the other. GRV revealed equal absorbance at 351 and 315 nm, for which the distinctions in absorbance we

APA, Harvard, Vancouver, ISO, and other styles

46

Karaoui, Lamis R., Hanine Mansour, and Elias B. Chahine. "Elbasvir–grazoprevir: A new direct-acting antiviral combination for hepatitis C." American Journal of Health-System Pharmacy 74, no. 19 (2017): 1533–40. http://dx.doi.org/10.2146/ajhp160558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

ÇELEN, Mustafa Kemal, İrem AKDEMİR, Recep TEKİN, Kadim BAYAN, and Celal AYAZ. "Elbasvir/Grazoprevir Experience- A New Glance at HCV Treatment: Case Report." Viral Hepatit Dergisi 23, no. 1 (2017): 34–36. http://dx.doi.org/10.4274/vhd.10337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Feng, Hwa-Ping, Luzelena Caro, Christine Fandozzi, et al. "Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 63, no. 4 (2019). http://dx.doi.org/10.1128/aac.02142-18.

Full text

Abstract:

ABSTRACT The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV). We explored the pharmacokinetic interactions of elbasvir and grazoprevir with ritonavir and ritonavir-boosted HIV protease inhibitors in three phase 1 trials. Drug-drug interaction trials with healthy participants were conducted to evaluate the effect of ritonavir on the pharmacokinetics of gra

APA, Harvard, Vancouver, ISO, and other styles

49

Gayathri, Kudithi, Gowthami Varri, P. V. Madhavi Latha, and P. Uma Devi. "METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF GRAZOPREVIR AND ELBASVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC." INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, October 1, 2022, 35–40. http://dx.doi.org/10.36106/ijsr/1001504.

Full text

Abstract:

A simple, Accurate and precise method was developed for the simultaneous estimation of Grazoprevir and Elbasvir Tablets. Chromatogram was run through Std Discovery C8 250 x 4.6 mm, 5m. Mobile phase containing Buffer 0.1% OPA: Acetonitrile taken in the ratio 45:55 was pumped through column at a ow rate of 1 ml/min. Buffer used in this method was 0.1% OPA buffer. Temperature was maintained at 30°C. Optimized wavelength selected was 260 nm. Retention time of Elbasvir and Grazoprevir and were found to be 2.503 min and 3.004. %RSD of the Elbasvir and Grazoprevir were and found to be 0.3 and 0.4 re

APA, Harvard, Vancouver, ISO, and other styles

50

"Elbasvir/grazoprevir." Reactions Weekly 1842, no. 1 (2021): 166. http://dx.doi.org/10.1007/s40278-021-90902-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!